Baxter International offers data backing flu vaccine

Baxter International says that a Phase I/II study of its bird flu vaccine demonstrates an immune response at low levels and is capable of cross immunization against several strains. Researchers said that they will now launch a Phase III trial in Europe to gauge the vaccine's effectiveness in a large group of healthy volunteers. Data is expected from the late-stage trial by the end of this year.

- read the MarketWatch report

ALSO: MedImmune has licensed its IP on reverse genetics to Sanofi-pasteur for use in developing a pandemic flu vaccine. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.